Strategy for Viral Safety Risk Reassessment with Changes in the Manufacturing Process of Recombinant Biotechnology Products

Wenbo Sai, Dongchen Jia, Hao Chen, Wei Wei

Engineering ›› 2024, Vol. 32 ›› Issue (1) : 14-17.

PDF(367 KB)
PDF(367 KB)
Engineering ›› 2024, Vol. 32 ›› Issue (1) : 14-17. DOI: 10.1016/j.eng.2023.10.003
Views & Comments

Strategy for Viral Safety Risk Reassessment with Changes in the Manufacturing Process of Recombinant Biotechnology Products

Author information +
History +

Graphical abstract

Cite this article

Download citation ▾
Wenbo Sai, Dongchen Jia, Hao Chen, Wei Wei. Strategy for Viral Safety Risk Reassessment with Changes in the Manufacturing Process of Recombinant Biotechnology Products. Engineering, 2024, 32(1): 14‒17 https://doi.org/10.1016/j.eng.2023.10.003

References

[[1]]
ICH Harmonised Tripartite Guideline.Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin Q5A(R1) [Internet]. Geneva: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 1999 Sep 23 [cited 2023 Aug 13].
[[2]]
ICH Harmonised Guideline.Technical and regulatory considerations for pharmaceutical product lifecycle management Q12 [Internet]. Geneva: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2017 Nov 16 [cited 2023 Aug 13].
[[3]]
S. Chinniah, P. Hinckley, L. Connell-Crowley. Characterization of operating parameters for XMuLV inactivation by low pH treatment. Biotechnol Prog, 32 (1) ( 2016), pp. 89-97
[[4]]
J. Mattila, S. Curtis, Y. Webb-Vargas, E. Wilson, O. Galperina, D. Roush, et al.. Retrospective evaluation of cycled resin in viral clearance studies—a multiple company collaboration. PDA J Pharm Sci Technol, 73 (5) ( 2019), pp. 470-486
[[5]]
G. Bolton, M. Cabatingan, M. Rubino, S. Lute, K. Brorson, M. Bailey. Normal-flow virus filtration: detection and assessment of the endpoint in bioprocessing. Biotechnol Appl Biochem, 42 (2) ( 2005), pp. 133-142
[[6]]
ICH Harmonised Guideline.Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin Q5A(R2) [Internet]. Geneva: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2022 Sep 29 [cited 2023 Aug 13].
[[7]]
P.U. Joshi, C.L. Meingast, X. Xu, M. Holstein, H. Feroz, S. Ranjan, et al.. Virus inactivation at moderately low pH varies with virus and buffer properties. Biotechnol J, 17 (2) ( 2022), p. 2100320
[[8]]
G. Miesegaes, S. Lute, K. Brorson. Analysis of viral clearance unit operations for monoclonal antibodies. Biotechnol Bioeng, 106 (2) ( 2010), pp. 238-246
[[9]]
L. Connell-Crowley, E.A. Larimore, R. Gillespie. Using high throughput screening to define virus clearance by chromatography resins. Biotechnol Bioeng, 110 (7) ( 2013), pp. 1984-1994
[[10]]
S. Curtis, K. Lee, G.S. Blank, K. Brorson, Y. Xu. Generic/matrix evaluation of SV40 clearance by anion exchange chromatography in flow-through mode. Biotechnol Bioeng, 84 (2) ( 2003), pp. 179-186
[[11]]
R. Specht, A. Schwantes.Proceedings of the 2019 Viral Clearance Symposium, Session 2:New Modalities in Chromatography and Adsorptive Filters. PDA J Pharm Sci Technol, 76 (4) ( 2022), pp. 306-314
[[12]]
L. Connell-Crowley, T. Nguyen, J. Bach, S. Chinniah, H. Bashiri, R. Gillespie, et al.. Cation exchange chromatography provides effective retrovirus clearance for antibody purification processes. Biotechnol Bioeng, 109 (1) ( 2012), pp. 157-165
[[13]]
M.R. Brown, S.A. Johnson, K.A. Brorson, S.C. Lute, D.J. Roush. A step-wise approach to define binding mechanisms of surrogate viral particles to multi-modal anion exchange resin in a single solute system. Biotechnol Bioeng, 114 (7) ( 2017), pp. 1487-1494
[[14]]
S. O’Donnell, G. Bolton.Proceedings of the 2019 Viral Clearance Symposium, Session 6:Virus-Retentive Filtration. PDA J Pharm Sci Technol, 76 (4) ( 2022), pp. 349-357
AI Summary AI Mindmap
PDF(367 KB)

Accesses

Citations

Detail

Sections
Recommended

/